With a national enterprise technology center and national postdoctoral research workstation, the company is a national high-tech enterprise, a national intellectual property demonstration enterprise, and also a technological innovation demonstration enterprise in Sichuan Province. The Company focuses on oncology therapeutics and pursues breakthrough innovations to achieve transformative clinical benefits for patients worldwide. It strategically prioritizes three cutting‑edge technology tracks: ADC (Antibody‑Drug Conjugate), ARC (Antibody‑Radionuclide Conjugate) and GNC (Multi‑specific T‑Cell Engager, TCE). Through the synergistic effect of ADC, ARC and GNC drug modalities, malignant tumors are expected to be gradually transformed into chronic, manageable diseases. This will prolong patients’ survival and improve their quality of life, ultimately enabling patients to achieve long‑term tumor‑bearing survival until the end of their natural lifespan.